Literature DB >> 28512190

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.

Paul Milne1, Venetia Bigley1, Chris M Bacon2,3, Antoine Néel4, Naomi McGovern1, Simon Bomken2, Muzlifah Haniffa1, Eli L Diamond5, Benjamin H Durham5, Johannes Visser6, David Hunt7, Harsha Gunawardena8, Mac Macheta9, Kenneth L McClain10, Carl Allen10, Omar Abdel-Wahab5, Matthew Collin1.   

Abstract

Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are rare histiocytic disorders induced by somatic mutation of MAPK pathway genes. BRAFV600E mutation is the most common mutation in both conditions and also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL). It is not known if adult LCH or ECD arises from hematopoietic stem cells (HSCs), nor which potential blood borne precursors lead to the formation of histiocytic lesions. In this study, BRAFV600E allele-specific polymerase chain reaction was used to map the neoplastic clone in 20 adults with LCH, ECD, and HCL. BRAFV600E was tracked to classical monocytes, nonclassical monocytes, and CD1c+ myeloid dendritic cells (DCs) in the blood, and mutations were observed in HSCs and myeloid progenitors in the bone marrow of 4 patients. The pattern of involvement of peripheral blood myeloid cells was indistinguishable between LCH and ECD, although the histiocytic disorders were distinct to HCL. As reported in children, detection of BRAFV600E in peripheral blood of adults was a marker of active multisystem LCH. The healthy counterparts of myeloid cells affected by BRAF mutation had a range of differentiation potentials depending on exogenous signals. CD1c+ DCs acquired high langerin and CD1a with granulocyte-macrophage colony-stimulating factor and transforming growth factor β alone, whereas CD14+ classical monocytes required additional notch ligation. Both classical and nonclassical monocytes, but not CD1c+ DCs, made foamy macrophages easily in vitro with macrophage colony-stimulating factor and human serum. These studies are consistent with a hematopoietic origin and >1 immediate cellular precursor in both LCH and ECD.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28512190      PMCID: PMC5524529          DOI: 10.1182/blood-2016-12-757823

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Authors:  Jean-François Emile; Eli L Diamond; Zofia Hélias-Rodzewicz; Fleur Cohen-Aubart; Frédéric Charlotte; David M Hyman; Eunhee Kim; Raajit Rampal; Minal Patel; Chezi Ganzel; Shlomzion Aumann; Gladwys Faucher; Catherine Le Gall; Karen Leroy; Magali Colombat; Jean-Emmanuel Kahn; Salim Trad; Philippe Nizard; Jean Donadieu; Valérie Taly; Zahir Amoura; Omar Abdel-Wahab; Julien Haroche
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

2.  BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.

Authors:  Felix Sahm; David Capper; Matthias Preusser; Jochen Meyer; Albrecht Stenzinger; Felix Lasitschka; Anna-Sophie Berghoff; Antje Habel; Marion Schneider; Andreas Kulozik; Ioannis Anagnostopoulos; Leonhard Müllauer; Gunhild Mechtersheimer; Andreas von Deimling
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

3.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

4.  Chester-Erdheim disease: a neoplastic disorder.

Authors:  J Chetritt; V Paradis; D Dargere; H Adle-Biassette; C A Maurage; J M Mussini; A Vital; J Wechsler; P Bedossa
Journal:  Hum Pathol       Date:  1999-09       Impact factor: 3.466

5.  Hand-Schüller-Christian disease and Erdheim-Chester disease: coexistence and discrepancy.

Authors:  Jun Yin; Feng Zhang; Huizhen Zhang; Li Shen; Qing Li; Shundong Hu; Qinghua Tian; Yuqian Bao; Weiping Jia
Journal:  Oncologist       Date:  2013-01-08

6.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

7.  A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes.

Authors:  Natsuki Hoshino; Naoyuki Katayama; Tetsunori Shibasaki; Kohshi Ohishi; Junji Nishioka; Masahiro Masuya; Yoshihiro Miyahara; Masahiko Hayashida; Daiki Shimomura; Takuma Kato; Kaname Nakatani; Kazuhiro Nishii; Kagemasa Kuribayashi; Tsutomu Nobori; Hiroshi Shiku
Journal:  J Leukoc Biol       Date:  2005-07-21       Impact factor: 4.962

8.  Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Authors:  Stephen S Chung; Eunhee Kim; Jae H Park; Christopher Y Park; Omar Abdel-Wahab; Young Rock Chung; Piro Lito; Julie Teruya-Feldstein; Wenhuo Hu; Wendy Beguelin; Sebastien Monette; Cihangir Duy; Raajit Rampal; Leon Telis; Minal Patel; Min Kyung Kim; Kety Huberman; Nancy Bouvier; Michael F Berger; Ari M Melnick; Neal Rosen; Martin S Tallman
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

9.  Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.

Authors:  C L Willman; L Busque; B B Griffith; B E Favara; K L McClain; M H Duncan; D G Gilliland
Journal:  N Engl J Med       Date:  1994-07-21       Impact factor: 91.245

10.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Authors:  Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen
Journal:  J Exp Med       Date:  2014-03-17       Impact factor: 14.307

View more
  44 in total

1.  Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.

Authors:  Pauline Bonnet; François Chasset; Philippe Moguelet; Noémie Abisror; Raphaël Itzykson; Jean-David Bouaziz; Pierre Hirsch; Annick Barbaud; Julien Haroche; Arsène Mekinian; Zofia Hélias-Rodzewicz; Emmanuelle Clappier; Pierre Fenaux; Olivier Fain; Abdellatif Tazi; Jean-François Emile
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

2.  Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia.

Authors:  Armin Ghobadi; Christopher A Miller; Tiandao Li; Michelle O'Laughlin; Yi-Shan Lee; Mohga Ali; Peter Westervelt; John F DiPersio; Lukas Wartman
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

Review 3.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

Review 4.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

Review 5.  Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Authors:  Oussama Abla; Eric Jacobsen; Jennifer Picarsic; Zdenka Krenova; Ronald Jaffe; Jean-Francois Emile; Benjamin H Durham; Jorge Braier; Frédéric Charlotte; Jean Donadieu; Fleur Cohen-Aubart; Carlos Rodriguez-Galindo; Carl Allen; James A Whitlock; Sheila Weitzman; Kenneth L McClain; Julien Haroche; Eli L Diamond
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

6.  Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder.

Authors:  Gadi Miron; Arnon Karni; Ahinoam Faust-Soher; Nir Giladi; Hilla Alroy; Avi Gadoth
Journal:  Neurol Clin Pract       Date:  2019-12

7.  Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms.

Authors:  Gaurav Goyal; Aishwarya Ravindran; Yuanhang Liu; Rong He; Mithun V Shah; N Nora Bennani; Mrinal M Patnaik; Karen L Rech; Ronald S Go
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

8.  Adult-onset Langerhans cell histiocytosis of the sternum.

Authors:  Yi-Jhih Huang; Kuan-Hsun Lin; Tai-Kuang Chao; Tsai-Wang Huang; Hsu-Kai Huang
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 9.  Erdheim-Chester Disease: a Concise Review.

Authors:  Matthias Papo; Jean-François Emile; Thiago Trovati Maciel; Pierre Bay; Alistair Baber; Olivier Hermine; Zahir Amoura; Julien Haroche
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

10.  Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.

Authors:  Ankush Bhatia; Vaios Hatzoglou; Gary Ulaner; Raajit Rampal; David M Hyman; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Mariko Yabe; Kseniya Petrova-Drus; Katherine S Panageas; Anne Reiner; Marc Rosenblum; Eli L Diamond
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.